World AIDS Day 2015: Paediatric HIV projects update from the team
World AIDS Day 2015: Paediatric HIV projects update from the team
At the close of 2015, we would like to take this opportunity to update you on the status of DNDi’s paediatric HIV 4-in-1 formulation development programme.
World AIDS Day 2015: Paediatric HIV projects update from the team
Breakthrough treatments for the most neglected diseases: diversifying approaches is required to expand the development pipeline with new chemical entities
Breakthrough treatments for the most neglected diseases: diversifying approaches is required to expand the development pipeline with new chemical entities
Graeme BilbeGraeme Bilbe, Research & Development Director, DNDi [November 2015] Addressing the lack of patient-adapted treatments for those suffering from neglected diseases is no easy task. DNDi’s initial short-term strategies were designed to quickly provide improved treatments through new formulations or combinations of existing drugs, and/or improved treatment regimens. Six new treatments have been delivered since 2003.
Breakthrough treatments for the most neglected diseases: diversifying approaches is required to expand the development pipeline with new chemical entities
R&D status November 2015: DNDi Filarial diseases programme
R&D status November 2015: DNDi Filarial diseases programme
[November 2015] Filarial diseases are caused by parasitic worms of the helminth family. They include onchocerciasis (also known as River Blindness), lymphatic filariasis (also known as elephantiasis), and loiasis (also known as African eye-worm). The worms are transmitted by insect vectors to humans, mainly in Africa and Southeast Asia. About 168 million people are infected by the three diseases.
R&D status November 2015: DNDi Filarial diseases programme
R&D status November 2015: DNDi Sleeping Sickness programme
R&D status November 2015: DNDi Sleeping Sickness programme
[November 2015] Human African trypanosomiasis (HAT), also known as ‘sleeping sickness’, is transmitted by the bite of a tsetse fly. While currently its prevalence is declining, 21 million people are still at risk across 36 Sub-Saharan Africa countries with most of the cases occurring in the Democratic Republic of Congo (89% of all cases in 2013).
R&D status November 2015: DNDi Sleeping Sickness programme
See all news

Scientific Articles

See all scientific articles

Events

  • Health for Sale: Debate on Access to Medicines and Innovation
    February 5, 2016
    The Hague, Netherlands
    During its Presidency of the Council of the European Union, the Government of the Netherlands has committed to improving affordable access to safe and effective medicines. But how can it create real and lasting change? Join public health experts and government representatives to debate these issues. The event is being coordinated by DNDi and other partners.
  • ASTMH in Kenya
    February 9, 2016
    Nairobi, Kenya
    DNDi is chairing and presenting at a symposium on innovation for access to treatment for neglected diseases at the first ASTMH in Kenya.
  • CTDDR 2016

    6th International Symposium on Current Trends in Drug Discovery and Research

    February 25-28, 2016
    Lucknow, India
    Robert Don, Graeme Bilbe, and Suman Rijal and will be presenting in a session on infectious diseases.
  • 17th International Congress on Infectious Diseases March 2-5, 2016 Hyderabad, India Suman Rijal, Director of DNDi Regional Office India, will be co-chairing a symposium on visceral leishmaniasis in South Asia, and Vishal Goyal, Clinical Manager, will be presenting.
  • Geneva Health Forum 2016 April 19-21, 2016 Geneva, Switzerland Carolina Batista, Regional Medical Manager, and Andrea Marchiol, Coordinator for the Chagas Operational Projects, will be presenting on access to treatment for Chagas disease.
See all events